TF and glioblastoma: An acid‐cleavable Tf‐modified engineering exosome‐based brain‐targeting delivery system (ACTE) was proposed using metabolic glycoengineering and bioorthogonal click chemistry, enabling co‐delivery of siTGF‐β and DOX for GBM treatment.